Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
LENZ Therapeutics, Inc. (LENZ)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$3.01-13.01%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for LENZ yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Operating losses improve from negative $44.1 million in Q1 2026 | A primary condition in LENZ Therapeutics, Inc.'s published investment case. The stated target is Operating income improves toward less negative than -44.1 USD_MILLIONS. | Broken | Operating losses worsen beyond negative $44.1 million | Operating income: $-32.918M FY2026-Q3; GAAP. Published target: Operating income improves toward less negative than -44.1 USD_MILLIONS. Target period is not explicitly aligned with this observation. Nov 3, 2026-32,918,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business, not an established earnings compounder: it is loss-making, with weak recent financial performance and elevated risk. The thesis is in a watch state after momentum weakened and the signal shifted from mildly favorable to mixed.
The valuation evidence describes LENZ as cheap versus peers, but confidence in that comparison is low. The negative expectations gap suggests the market outlook is cautious, while the overall priced-in tag is justified and no fragility gates fired.
Near term, the latest results included an earnings miss and an operating loss, while company momentum fell sharply. VIZZ sales rose sequentially to $2.599 million on more than 38,000 paid prescriptions, but the planned reduction in 2027 operating expenses is still a commitment rather than a demonstrated result.
The multi-year view hinges on continued VIZZ adoption, delivery of the cost reductions, and broader progress in international commercialization. Near term, a guidance cut or further labor-market weakness could add pressure; continued strong results from healthcare sector bellwethers would be a supportive sector signal.
LENZ has early commercial progress, but weak recent performance and unproven cost-cut delivery leave the 1-to-3-year thesis uncertain. The next evidence on VIZZ adoption, expenses, and guidance matters. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Successful product launches including telehealth services | Telehealth launch supports revenue growth. | Improving | No new product launches or telehealth expansion fails | VIZZ scripts +45% MoM vs target of sustained launches VIZZ scripts +45% MoM; telehealth launch active; 75% headcount reduction; earnings miss. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue reaches about $1.9 million in Q3 2026 | A primary condition in LENZ Therapeutics, Inc.'s published investment case. The stated target is >=1.9 USD_MILLIONS. | Intact | Revenue falls below $1.6 million in Q3 2026 | Revenue: $3.384M FY2026-Q3; GAAP. Published target: >=1.9 USD_MILLIONS. Same fiscal period as the stored target. Nov 3, 20263,384,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.51 → $-1.18 · observed estimates
$0.06B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-07-25 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-07-26 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-07-27 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-07-28 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-07-29 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-07-30 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-07-31 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-08-01 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-02 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-08-03 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-08-04 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-08-05 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-06 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-07 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-08 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-08-09 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-10 | $-3.51 | $63,179,900 | 7 / 7 |
| 2026-08-12 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-13 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-14 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-15 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-16 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-17 | $-3.42 | $63,174,043 | 6 / 5 |
| 2026-08-18 | $-3.42 | $63,174,043 | 5 / 5 |
| 2026-08-19 | $-3.42 | $63,174,043 | 5 / 5 |
| 2026-08-20 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-21 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-22 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-23 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-24 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-25 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-26 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-27 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-28 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-29 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-30 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-08-31 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-01 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-02 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-03 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-04 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-05 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-06 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-07 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-08 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-09 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-10 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-11 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-12 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-13 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-14 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-15 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-16 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-17 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-18 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-19 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-20 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-21 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-22 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-23 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-24 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-25 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-26 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-27 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-28 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-29 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-09-30 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-01 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-02 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-03 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-04 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-05 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-06 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-07 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-08 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-09 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-10 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-11 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-12 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-13 | $-2.72 | $42,989,715 | 5 / 5 |
| 2026-10-14 | $-2.58 | $42,851,129 | 5 / 5 |
| 2026-10-15 | $-2.58 | $42,851,129 | 5 / 5 |
| 2026-10-16 | $-2.58 | $42,851,129 | 5 / 5 |
| 2026-10-17 | $-2.58 | $42,851,129 | 5 / 5 |
| 2026-10-18 | $-2.58 | $42,851,129 | 5 / 5 |
| 2026-10-19 | $-2.58 | $42,851,129 | 5 / 5 |
| 2026-10-20 | $-2.56 | $41,836,843 | 5 / 5 |
| 2026-10-21 | $-2.56 | $41,836,843 | 5 / 5 |
| 2026-10-22 | $-2.38 | $37,551,129 | 5 / 5 |
| 2026-10-23 | $-2.38 | $37,551,129 | 5 / 5 |
| 2026-10-24 | $-2.38 | $37,551,129 | 5 / 5 |
| 2026-10-25 | $-2.38 | $37,551,129 | 5 / 5 |
| 2026-10-26 | $-2.38 | $37,551,129 | 5 / 5 |
| 2026-10-27 | $-2.38 | $37,551,129 | 5 / 5 |
| 2026-10-28 | $-2.38 | $37,551,129 | 5 / 5 |
| 2026-10-29 | $-2.31 | $36,832,572 | 5 / 5 |
| 2026-10-30 | $-1.59 | $34,881,764 | 5 / 5 |
| 2026-10-31 | $-1.18 | $32,666,192 | 5 / 5 |
| 2026-11-01 | $-1.18 | $32,666,192 | 5 / 5 |
| 2026-11-02 | $-1.18 | $32,666,192 | 5 / 5 |
| 2026-11-03 | $-1.18 | $32,666,192 | 5 / 5 |
| 2026-11-04 | $-1.18 | $32,666,192 | 5 / 5 |
| 2026-11-05 | $-1.18 | $32,666,192 | 5 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 4 recorded
0 raises · 1 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
1 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.